Discover how chemically induced nuclear pore complex protein degradation via TRIM21 is revolutionizing targeted protein degradation therapies for cancer and neurodegenerative diseases.
Discover how first-in-class molecular glue degraders target AR-V7 in treatment-resistant prostate cancer, offering new hope for patients.